Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fluticasone Propionate

FDA-approved product (ointment, topical), marketed as Armonair Digihaler, Armonair Respiclick, Cutivate and 9 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Fluticasone Propionate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Airway obstruction
  • Allergic rhinitis
  • Asthma
  • Atopic eczema
  • Chronic bronchitis
  • Chronic obstructive pulmonary disease
  • Emphysema
  • Nasal Cavity Polyp
  • Nasal congestion
  • Nasal polyposis
  • Seasonal allergic rhinitis
  • Skin disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids, potent (group iii); Corticosteroids; Glucocorticoids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fluticasone Propionate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fluticasone Propionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma

    NCT00736801 · start 2005-09

    Registered record
    Registry ID
    NCT00736801
    Conditions
    Allergic Asthma
    Interventions
    Salmeterol and Salmeterol / Fluticasone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-09
    Completion
    2007-04
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Asthma
    InterventionSalmeterol and Salmeterol / Fluticasone
    PhaseNot applicable
    Registry statusCompleted

  • The Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Inflammometry

    NCT00402207 · start 2005-08

    Registered record
    Registry ID
    NCT00402207
    Conditions
    Asthma
    Interventions
    extrafine HFA-beclomethasone; HFA-fluticasone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-08
    Completion
    2006-10
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    Interventionextrafine HFA-beclomethasone; HFA-fluticasone
    PhaseNot applicable
    Registry statusCompleted

  • Protopic Ointment in Adult Atopic Eczema of the Face

    NCT00690105 · start 2004-02

    Registered record
    Registry ID
    NCT00690105
    Conditions
    Dermatitis, Atopic
    Interventions
    tacrolimus 0.1%; fluticasone 0.005 %
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-02
    Completion
    2005-07
    Enrolment
    577

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatitis, Atopic
    Interventiontacrolimus 0.1%; fluticasone 0.005 %
    PhasePhase 4
    Registry statusCompleted

  • Comparison of Two Treatment Regimens in Asthmatic Patients

    NCT01488773 · start 1995-04

    Registered record
    Registry ID
    NCT01488773
    Conditions
    Asthma
    Interventions
    first prescription of montelukast; first prescription of salmeterol
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    1995-04
    Completion
    2006-06
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    Interventionfirst prescription of montelukast; first prescription of salmeterol
    PhaseNot recorded
    Registry statusCompleted

  • Expanded Access Protocol for Patients With Eosinophilic Esophagitis

    NCT05095116

    Registered record
    Registry ID
    NCT05095116
    Conditions
    Eosinophilic Esophagitis
    Interventions
    APT-1011 3 mg HS
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEosinophilic Esophagitis
    InterventionAPT-1011 3 mg HS
    PhaseNot recorded
    Registry statusNo longer available